Philip Morris International (NYSE:PM) just turned a $600 million plan into a $1.2 billion one. On July 27, the company opened its Aurora, Colorado manufacturing campus, a 780,000-square-foot facility built to produce ZYN nicotine pouches. The site went from groundbreaking to commercial shipments in about 19 months, and it opened just weeks after regulators handed ZYN a marketing edge no other nicotine pouch product has. For a company still known mostly for Marlboro, that combination says a lot about where its growth is actually coming from.
The Bull Case: A New Home For Zyn’s Growth
Aurora is PMI’s first greenfield manufacturing complex in the US, built on 148 acres and designed to combine production, packaging, warehousing, and distribution in one location. About $1 billion of the planned $1.2 billion has already gone into the project, and the campus is expected to directly employ roughly 500 people once fully staffed. Company estimates point to about $550 million in annual economic impact and another 1,000 indirect jobs once it reaches full operation. Aurora also joins existing PMI facilities in Owensboro, Kentucky, and Wilson, North Carolina, expanding its smoke manufacturing footprint, and as per the company, the reach to export ZYN into Asia, Latin America and the Caribbean.
The timing lines up with a regulatory win. On June 30, the FDA authorized 20 ZYN products as modified risk tobacco products, making ZYN the first nicotine pouch allowed to market itself as lower risk than cigarettes. Reuters reported that Philip Morris also beat second-quarter estimates in July, with the company crediting demand for its smoke-free lineup and stronger-than expected ciggratte demand, which spans ZYN, the IQOS heated-tobacco device and vapor products.
The Bear Case: Velo Max And The Price Of Scale
None of this comes cheap. The Aurora project doubled in cost from its original $600 million estimate, a reminder that scaling nicotine pouch manufacturing this fast requires real, and rising, capital through 2028. That spending is also concentrated on a single product category just as the competitive field gets more crowded. British American Tobacco (NYSE:BTI), Philip Morris’s closest rival in smoke-free nicotine, said on July 30 that its overall New Categories revenue grew 18.0% at constant exchange rates in H1 2026.
Within that business, Modern Oral revenue increased 65.9%, driven partly by Velo Plus and Grizzly Modern Oral in the US. BAT’s Modern Oral portfolio reached a 39.2% volume share across its designated top markets. BAT plans to roll out its higher-strength Velo Max nationally in the US during H2 2026, aiming at the same shelf space ZYN is fighting for. BAT is backing that push with a £1.3 billion share buyback program it says remains on track for 2026, a sign it sees enough cash flow to fund both the launch and shareholder returns at once. If Velo Max gains real traction against ZYN just as Philip Morris brings its most expensive US plant online, the payback period on Aurora gets longer. Competitive pressure also exists, evident in PMI numbers. US segment revenue declined 16.5% organically in the first six months, partly because of inventory movements and difficult promotional comparisons.
What The Market Is Pricing In
Hedge fund ownership of Philip Morris slipped modestly from 82 funds to 78 in the most recent quarter. British American Tobacco moved the other way, with its count ticking modestly up from 40 to 41. As for short interest, 1.12% of Philip Morris’s float were sold short against just 0.40% for BAT. Short interest remains low for both companies. Philip Morris also trades at a forward P/E of 22.62, as of August 5, nearly double BAT’s 12.42, pricing in faster growth for ZYN.
The Multiple Now Has To Deliver
Philip Morris now has the manufacturing footprint, the FDA’s blessing, and Street’s growth expectations lined up behind ZYN. What isn’t settled is whether that growth story already justifies the stock’s premium over British American Tobacco.
While we acknowledge the risk and potential of PM and BTI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PM and BTI and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center